BioArts International, a biotech company in the San Francisco area, has discontinued its commercial dog cloning services. As such, the company has also ended its partnership with South Korean cloning vendor Sooam Biotech Research Foundation and its head Dr. Hwang Woo-Suk.
The fifth and final set of cloned dogs was delivered in September.
Lou Hawthorne, chief executive officer, cited a list of reasons why the company made its decision, a tiny market being one of them. […]
Hawthorne also blamed black market competition. A company that would offer the same services would be in violation of international patents, he said, because BioArts holds the sole, worldwide rights to clone dogs, cats and endangered species.
For instance, a South Korean biotech company advertised in February 2008 that it would clone dogs at a fraction of BioArts’ price, starting at $150,000 and then down to $30,000.
1 Comment
© 2024 Technoccult
Theme by Anders Norén — Up ↑
May 25, 2011 at 6:10 pm
There are definitely loads of particulars like that to take into consideration. That may be a great level to convey up. I provide the ideas above as normal inspiration however clearly there are questions just like the one you carry up the place an important factor can be working in sincere good faith. I don?t know if best practices have emerged around things like that, however I am positive that your job is clearly identified as a good game. Both girls and boys feel the affect of just a momentís pleasure, for the remainder of their lives.